ADC Therapeutics Announces Q4 and Year-End 2024 Conference Call
ADC Therapeutics SA (NYSE: ADCT), a leader in the development of antibody drug conjugates (ADCs), has exciting news for investors and stakeholders. The company announced it will hold a conference call on March 27, 2025, to discuss the financial results for the fourth quarter and the fiscal year ending December 31, 2024. This pivotal event will take place live at 8:30 a.m. EDT, and it promises to offer insights into the company’s financial health and future operational plans.
Conference Call Details and Access Information
Interested participants can register for the conference call, which will be accessible through a live webcast. It is highly recommended for participants to join the call ten minutes prior to its start. A toll-free dial-in number is provided for North American participants, ensuring easy access to this essential meeting.
During this call, executives from ADC Therapeutics will detail their financial performance alongside exciting updates about their ongoing projects in the innovative field of ADCs. This is an opportunity for investors to gain valuable insights into the company's strategy and future direction.
About ADC Therapeutics and Their Innovations
ADC Therapeutics is redefining the treatment landscape for patients grappling with hematologic malignancies and solid tumors through its pioneering ADC technology. The company’s flagship product, ZYNLONTA (loncastuximab tesirine-lpyl), has garnered both accelerated approval by the FDA and conditional approval from European authorities for treating patients with relapsed or refractory diffuse large B-cell lymphoma after extensive prior therapies.
Not stopping with ZYNLONTA, ADC Therapeutics is advancing a robust pipeline of ADC candidates, each aimed at overcoming the challenges presented by various cancers. The company continues to innovate and explore the possibilities of combining ZYNLONTA with other therapies, enhancing treatment options for patients.
Company Growth and Future Outlook
Headquartered in Lausanne, ADC Therapeutics boasts a strong team dedicated to driving the next wave of cancer treatment solutions. The recent advancements affirm the company’s commitment to leveraging its proprietary ADC technology to significantly enhance patient outcomes.
With operations that extend to London and New Jersey, ADC Therapeutics remains at the forefront of oncology innovation. Investors and stakeholders can expect ongoing developments as the company pursues its mission to provide advanced therapies for cancer treatment.
Frequently Asked Questions
When will the conference call take place?
The conference call is scheduled for March 27, 2025, at 8:30 a.m. EDT.
How can I join the conference call?
Participants can register for the call and join via a toll-free dial-in number for North America. A live webcast will also be available for a broader audience.
What is ZYNLONTA?
ZYNLONTA is an FDA-approved ADC used for treating relapsed or refractory diffuse large B-cell lymphoma, representing a significant advancement in cancer treatment.
Where is ADC Therapeutics located?
ADC Therapeutics is headquartered in Lausanne, Switzerland, with additional offices in London and New Jersey.
What can we expect from ADC Therapeutics in the future?
Investors can anticipate ongoing advancements in ADC technologies and the expansion of treatment options for cancer patients as ADC Therapeutics pushes forward with its innovative pipeline.
